drugset / Trial / NCT03703856

Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease

NCT03703856

Phase 4 Completed 53 enrolled University of California, San Diego
NaSingle-groupOpen-labelTreatment

Summary

The effects of the medication, memantine, on brain functions and the symptoms of Alzheimer's Disease will be tested

Timeline

Start
2019-01-31
Primary completion
2025-01-08
Completion
2025-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Memantine Unknown 10 mg Oral
Subject Memantine Unknown 20 mg Oral

Indications